{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:39:41Z","timestamp":1792643981245,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1067\/mhj.2001.119374","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T18:14:26Z","timestamp":1030212866000},"page":"952-959","source":"Crossref","is-referenced-by-count":272,"title":["Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study"],"prefix":"10.1067","volume":"142","author":[{"given":"John A.","family":"Bittl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard R.","family":"Chaitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mhj.2001.119374_bib1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"New Engl J Med"},{"key":"10.1067\/mhj.2001.119374_bib2","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","article-title":"Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial","volume":"352","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2001.119374_bib3","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"The ESPRIT study: a randomised, placebo-controlled trial of a novel dosing regimen of eptifibatide in planned coronary stent implantation","volume":"356","author":"ESPRIT Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1067\/mhj.2001.119374_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal ACT during percutaneous coronary intervention: aggregate results from six randomized controlled trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib6","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/01.CIR.89.4.1523","article-title":"Heparin neutralization by platelet-rich thrombi: role of platelet factor 4","volume":"89","author":"Eitzmann","year":"1994","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1067\/mhj.2001.119374_bib8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.CIR.93.4.667","article-title":"Relation between activated clotting time during angioplasty and abrupt closure","volume":"93","author":"Narins","year":"1996","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.CIR.92.3.311","article-title":"Length of hospital stay and complications after percutaneous transluminal coronary angioplasty: clinical and procedural predictors","volume":"92","author":"Wolfe","year":"1995","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib10","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","article-title":"Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO): Hirulog Early Reperfusion\/Occlusion (HERO) Trial Investigators","volume":"96","author":"White","year":"1997","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib11","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.CIR.100.20.2049","article-title":"Clinical outcomes of bivalirudin for acute coronary syndromes","volume":"100","author":"Kong","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.87.5.1622","article-title":"Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty","volume":"87","author":"Topol","year":"1993","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2001.119374_bib14","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1161\/01.CIR.88.6.2987","volume":"88","author":"Ryan","year":"1993","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0735-1097(97)00506-8","article-title":"Myonecrosis after revascularization procedures","volume":"31","author":"Califf","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2001.119374_bib16","doi-asserted-by":"crossref","first-page":"486S","DOI":"10.1378\/chest.108.4_Supplement.486S","article-title":"Antithrombotic therapy in patients undergoing coronary angioplasty","volume":"108","author":"Popma","year":"1995","journal-title":"Chest"},{"key":"10.1067\/mhj.2001.119374_bib17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.90.4.1638","article-title":"Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhaus\u00e4rzte (ALK)","volume":"90","author":"Neuhaus","year":"1994","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib18","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.89.4.1557","article-title":"Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial","volume":"89","author":"Topol","year":"1994","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib19","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","article-title":"Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial","volume":"90","author":"Antman","year":"1994","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial","volume":"353","author":"Organisation to Assess Strategies for Ischemic Syndromes OASIS-2 Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2001.119374_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","article-title":"A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty","volume":"333","author":"Serruys","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2001.119374_bib22","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1067\/mhj.2001.119374_bib23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2001.119374_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/01.CIR.91.3.619","article-title":"Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes","volume":"91","author":"Annex","year":"1995","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.119374_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/380041a0","article-title":"The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor","volume":"380","author":"Banner","year":"1996","journal-title":"Nature"},{"key":"10.1067\/mhj.2001.119374_bib27","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/0735-1097(94)90144-9","article-title":"Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty","volume":"24","author":"Marmur","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2001.119374_bib28","doi-asserted-by":"crossref","first-page":"50P","DOI":"10.1016\/S0002-9149(98)00760-7","article-title":"Relation between the risk of abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty","volume":"82","author":"Bittl","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2001.119374_bib29","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"Biochemistry"},{"key":"10.1067\/mhj.2001.119374_bib30","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1021\/bi00253a020","article-title":"Kinetic mechanism for the interaction of Hirulog with thrombin","volume":"33","author":"Parry","year":"1994","journal-title":"Biochemistry"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870301018737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870301018737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T09:27:40Z","timestamp":1557394060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870301018737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S0002870301018737"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2001.119374","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}